Literature DB >> 33587283

Eczematous Drug Eruptions.

Amy E Blum1, Susan Burgin2,3.   

Abstract

Eczematous drug eruptions are a heterogenous group of skin reactions that resemble eczema both clinically and histologically. We reviewed the literature and cataloged the systemically administered medications that cause these eruptions, along with their characteristic clinical presentations. We identified three primary pathophysiologic etiologies: (1) cutaneous immunomodulation, (2) skin dehydration, and (3) delayed hypersensitivity. Notably, eczematous eruptions caused by altered immunity in the skin may be increasing in incidence as some responsible drugs, in particular biologic therapies (such as tumor necrosis factor-α and interleukin-17 inhibitors) and targeted cancer treatments (including immune checkpoint inhibitors and epidermal growth factor receptor inhibitors), become more commonly employed in clinical practice. Other notable causes of eczematous eruptions include antiviral agents for hepatitis C virus and cardiovascular medications in elderly individuals, and notable subtypes of eczematous reactions include systemic contact dermatitis and photoallergic reactions, which are also discussed. The diagnostic gold standard is drug rechallenge and most reactions may be treated effectively with emollients, topical corticosteroids, and oral antihistamines.

Entities:  

Year:  2021        PMID: 33587283     DOI: 10.1007/s40257-021-00586-8

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  151 in total

1.  Drug eruptions: a study including all inpatients and outpatients at a dermatology clinic of a university hospital.

Authors:  R Apaydin; N Bilen; S Dökmeci; D Bayramgürler; G Yildirim
Journal:  J Eur Acad Dermatol Venereol       Date:  2000-11       Impact factor: 6.166

2.  Skin Manifestations in Pediatric Patients Treated With a TNF-Alpha Inhibitor for Inflammatory Bowel Disease: A Retrospective Study [Formula: see text].

Authors:  María-Laura Cossio; Annie Genois; Prévost Jantchou; Afshin Hatami; Colette Deslandres; Catherine McCuaig
Journal:  J Cutan Med Surg       Date:  2020-06-11       Impact factor: 2.092

3.  The use of skin testing in the investigation of cutaneous adverse drug reactions.

Authors:  A Barbaud; S Reichert-Penetrat; P Tréchot; M A Jacquin-Petit; A Ehlinger; V Noirez; G C Faure; J L Schmutz; M C Béné
Journal:  Br J Dermatol       Date:  1998-07       Impact factor: 9.302

Review 4.  Clinical Signs, Pathophysiology and Management of Cutaneous Side Effects of Anti-Tumor Necrosis Factor Agents.

Authors:  Siegfried Segaert; Caroline Hermans
Journal:  Am J Clin Dermatol       Date:  2017-12       Impact factor: 7.403

5.  Concomitant use of azathioprine/6-mercaptopurine decreases the risk of anti-TNF-induced skin lesions.

Authors:  Jae Seung Soh; Woo Jin Yun; Kyung-Jo Kim; Chong Hyun Won; Sang Hyoung Park; Dong-Hoon Yang; Byong Duk Ye; Jeong-Sik Byeon; Seung-Jae Myung; Suk-Kyun Yang; Jin-Ho Kim
Journal:  Inflamm Bowel Dis       Date:  2015-04       Impact factor: 5.325

Review 6.  Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review.

Authors:  A Al-Janabi; A C Foulkes; K Mason; C H Smith; C E M Griffiths; R B Warren
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-02-27       Impact factor: 6.166

7.  Ustekinumab for skin reactions associated with anti-tumor necrosis factor-α agents in patients with inflammatory bowel diseases: A single-center retrospective study.

Authors:  Khaled Ezzedine; Laetitia Visseaux; Guillaume Cadiot; Hedia Brixi; Philippe Bernard; Ziad Reguiai
Journal:  J Dermatol       Date:  2019-02-28       Impact factor: 4.005

8.  The prevalence of acute cutaneous drug reactions in a Scandinavian university hospital.

Authors:  Jakob E Borch; Klaus E Andersen; Carsten Bindslev-Jensen
Journal:  Acta Derm Venereol       Date:  2006       Impact factor: 4.437

9.  The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.

Authors:  Anita Afzali; Chelle L Wheat; Jie Kate Hu; John E Olerud; Scott D Lee
Journal:  J Crohns Colitis       Date:  2013-11-21       Impact factor: 9.071

10.  Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.

Authors:  Cornelia Tillack; Laura Maximiliane Ehmann; Matthias Friedrich; Rüdiger P Laubender; Pavol Papay; Harald Vogelsang; Johannes Stallhofer; Florian Beigel; Andrea Bedynek; Martin Wetzke; Harald Maier; Maria Koburger; Johanna Wagner; Jürgen Glas; Julia Diegelmann; Sarah Koglin; Yvonne Dombrowski; Jürgen Schauber; Andreas Wollenberg; Stephan Brand
Journal:  Gut       Date:  2013-03-06       Impact factor: 23.059

View more
  1 in total

1.  Exanthematous Drug Eruption to Intravenous Iron: A Case Report.

Authors:  Shilpa S Mantri; Niraj Ballam Nagaraj; Chirag Patel; Kinjal Solanki; Haris Rana
Journal:  Cureus       Date:  2022-02-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.